JOHNSON & JOHNSON – Group report and key figures

IN THIS XERFI GLOBAL REPORT :

WHAT IS THE GROUP'S FINANCIAL SITUATION ?

The financial indicators presented in this report include: consolidated revenue, consolidated EBIT and EBIT ratio, consolidated net profit and net profit rate, R&D expenditure and ratio, sales by segment and by region, profitability, liquidity and solvency ratios, free cash flow and capital expenditure.

WHAT ARE THE GROUP'S STRATEGIC PRIORITIES ?

Launch ten $5 billion pharma assets by 2030

Develop MedTech unit into a major sector player

Restructure to focus on most profitable programmes

WHAT ARE THE GROUP'S STRENGTHS AND WEAKNESSES ?

Through a SWOT analysis, this report also provides an overview of the group's strengths (strong innovation pipeline and a leading global R&D spender, etc.) and weaknesses (one market—the US—accounts for more than half of turnover, etc.).

1. Overview

Presentation

Segments

SWOT

2. Corporate Strategies and Recent Events

3. Financial Indicators

4. Statistical Appendix

5. Glossary